OH-PARKER-AEROSPACE
24.4.2024 16:01:32 CEST | Business Wire | Press release
Parker Aerospace, a business segment of Parker Hannifin Corporation, the global leader in motion and control technologies, will participate in the HyFIVE consortium of industry and academic partners developing a world-leading liquid hydrogen fuel system and supply chain supporting zero-emission aviation in the 2030s.
In addition to Parker Aerospace, HyFIVE includes fellow industry partners Marshall and GKN Aerospace, as well as academic partners University of Manchester, University of Bath and Cardiff University. The project is supported by the ATI Programme, a partnership between the UK’s Department for Business and Trade, the Aerospace Technology Institute (ATI) and Innovate UK (UKRI). The consortium will receive initial funding of £17 million ($21.5 million) from industry, matched by £20 million ($25 million) from the UK Government.
A path to zero emissions flight
The objective of the HyFIVE consortium is to develop, test and validate a modular and scalable cryogenic hydrogen fuel system architecture appropriate for multiple types of aircraft, and support of hydrogen electric propulsion or hydrogen combustion powertrains. The initiative will address technology development for hydrogen fuel systems in five key areas: storage, conveyance, indication, fueling and venting.
Collaboration among industry leaders
Parker Aerospace, which includes Parker Meggitt, has a broad spectrum of solutions for both airframes and engines and will furnish its advanced technology and expertise in the areas of sensing, thermal management and fluid conveyance.
Marshall will be leading the HyFIVE efforts, providing its expertise in complex system design, integration and certification, honed over decades of delivering aircraft fuel systems and complex aircraft modification projects.
GKN Aerospace, specializing in the design, manufacture and assembly of aircraft structures, engine components and systems, will contribute its industry-leading advanced materials and hydrogen cryogenic system optimization expertise.
Academic partners University of Manchester, University of Bath and Cardiff University have been selected for their world-leading research capabilities and advanced testing facilities in the areas of hydrogen-electric propulsion, cryogenic applications, power transmission, turbomachinery and next-generation material development.
Technical program detailed
The HyFIVE consortium members have defined a full technical program spanning several years, from initial architecture development and supplier engagement to ground testing and final design review for the integrated fuel system.
By 2027, the consortium plans to:
- Develop and validate an integrated family of mature fuel system technologies and capabilities conducive to certification.
- Conduct ground demonstration of an integrated fuel system encompassing the storage, conveyance, indication, venting and fueling systems.
- Open a range of flight demonstration and exploitation paths with prospective customers.
- Develop a customer-ready supply chain and industrialization strategy.
The timely achievement of these objectives will support the successful introduction of a new generation of zero-emissions aircraft in the 2030s.
"Parker is fully committed to sustainability, which is why we are making focused investments in innovative, next-generation technologies,” said Tracy Rice, vice president of technology and innovation for Parker Aerospace. “Hydrogen fuel systems play a critical role in achieving zero emissions in aviation and working with our partners on this project will enable us to further advance our expertise in this area and drive the development of innovative solutions that support a more sustainable future.”
About Parker Aerospace. At Parker Aerospace, we develop technologies and innovative solutions that enable reliable, efficient and increasingly sustainable flight for the lifecycle of the aircraft, including aftermarket support. Parker stands at the forefront of aviation technology with an expanded range of products and services that sits nose-to-tail across the entire aircraft. Our passionate people with deep engineering expertise, together with our breadth of differentiated technologies, ensure that we make the extraordinary happen and continue to shape the future of aviation in partnership with our customers.
About Parker Hannifin. Parker is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Learn more at www.parker.com or @parkerhannifin.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424285169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
